KR102753110B1 - Bcl-2-관련된 데스 프로모터(bad) 인산화의 소분자 억제제 - Google Patents

Bcl-2-관련된 데스 프로모터(bad) 인산화의 소분자 억제제 Download PDF

Info

Publication number
KR102753110B1
KR102753110B1 KR1020197034039A KR20197034039A KR102753110B1 KR 102753110 B1 KR102753110 B1 KR 102753110B1 KR 1020197034039 A KR1020197034039 A KR 1020197034039A KR 20197034039 A KR20197034039 A KR 20197034039A KR 102753110 B1 KR102753110 B1 KR 102753110B1
Authority
KR
South Korea
Prior art keywords
compound
methyl
piperazin
dichlorophenyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034039A
Other languages
English (en)
Korean (ko)
Other versions
KR20200029384A (ko
Inventor
피터 에드워드 로비
비제이 쿠마르 판데이
랑가파 칸추가라코팔 서브베고다
바사파 살룬디
모한 차크랍하비 단자야
쇼비츠 랑가파
스리니바사 벤카타챠라이아
Original Assignee
싱가포르국립대학교
마이소르대학교
방갈로르 유니버서티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싱가포르국립대학교, 마이소르대학교, 방갈로르 유니버서티 filed Critical 싱가포르국립대학교
Publication of KR20200029384A publication Critical patent/KR20200029384A/ko
Application granted granted Critical
Publication of KR102753110B1 publication Critical patent/KR102753110B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
KR1020197034039A 2017-04-19 2018-04-18 Bcl-2-관련된 데스 프로모터(bad) 인산화의 소분자 억제제 Active KR102753110B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1706162.3 2017-04-19
GBGB1706162.3A GB201706162D0 (en) 2017-04-19 2017-04-19 Compounds
PCT/SG2018/050194 WO2018194520A1 (en) 2017-04-19 2018-04-18 Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation

Publications (2)

Publication Number Publication Date
KR20200029384A KR20200029384A (ko) 2020-03-18
KR102753110B1 true KR102753110B1 (ko) 2025-01-09

Family

ID=58744515

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197034039A Active KR102753110B1 (ko) 2017-04-19 2018-04-18 Bcl-2-관련된 데스 프로모터(bad) 인산화의 소분자 억제제

Country Status (12)

Country Link
US (1) US11292773B2 (https=)
EP (1) EP3612518A4 (https=)
JP (1) JP7423010B2 (https=)
KR (1) KR102753110B1 (https=)
CN (1) CN110719906B (https=)
AU (1) AU2018256285B2 (https=)
CA (1) CA3060939A1 (https=)
GB (1) GB201706162D0 (https=)
IL (1) IL270078B (https=)
MX (1) MX2024000001A (https=)
SG (1) SG11201909418WA (https=)
WO (1) WO2018194520A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN112481298A (zh) * 2020-11-11 2021-03-12 清华-伯克利深圳学院筹备办公室 重组质粒及其应用
CN115340527B (zh) * 2021-05-13 2023-09-15 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518493A (ja) * 1998-06-25 2002-06-25 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド ３−アリール−ベンゾフラノンの製造方法
JP2003505420A (ja) * 1999-07-26 2003-02-12 シェーリング コーポレイション 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１
JP2007508350A (ja) * 2003-10-15 2007-04-05 イーエムテーエム ゲーエムベーハー 異なる細胞に機能的に影響を及ぼし、免疫性疾患、炎症性疾患、神経疾患、およびその他の疾患を治療するための二重のアラニルアミノペプチダーゼおよびジペプチジルペプチダーゼｉｖの阻害剤
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
US20130096133A1 (en) * 2011-10-14 2013-04-18 The Board of Trustees of the University lllinois Procaspase-activating compounds and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
JP2017128541A (ja) * 2016-01-21 2017-07-27 学校法人東京女子医科大学 アポトーシス誘導剤
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518493A (ja) * 1998-06-25 2002-06-25 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド ３−アリール−ベンゾフラノンの製造方法
JP2003505420A (ja) * 1999-07-26 2003-02-12 シェーリング コーポレイション 咳を処置するのに使用するノシセプチンレセプタｏｒｌ−１
JP2007508350A (ja) * 2003-10-15 2007-04-05 イーエムテーエム ゲーエムベーハー 異なる細胞に機能的に影響を及ぼし、免疫性疾患、炎症性疾患、神経疾患、およびその他の疾患を治療するための二重のアラニルアミノペプチダーゼおよびジペプチジルペプチダーゼｉｖの阻害剤
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
US20130096133A1 (en) * 2011-10-14 2013-04-18 The Board of Trustees of the University lllinois Procaspase-activating compounds and compositions

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Christov, K. 외, Clin Cancer Res 2007, 13, 5488-5496*
Doan, P. 외, European Journal of Medicinal Chemistry 2016, 120, 296-303*
El Kaim, L. 외, Org. Biomol. Chem. 2006, 4, 3410-3413*
Erb, W. 외, J. Org. Chem. 2014, 79, 10568-10580*
He, X. 외, J. Org. Chem. 2016, 81, 2062-2069*
Hosseinzadeh, R. 외, J. Iran. Chem. Soc. 2017, 14, 347-355*
Katritzky, A. R. 외, J. Org. Chem. 1999, 64, 6071-6075*
Lin, J.-C. 외, Food Chem. Tox. 2007, 45, 935-944*
Neto, I. 외, ChemMedChem 2016, 11, 2015-2023*
Richard, D. J. 외, Bioorg. Med. Chem. 2013, 21, 6642-6649*
Schlienger, N. 외, Tetrahedron, 2000, 56 10023-10030*
STN RN 1088182-85-7 (2008)*
STN RN 1797320-83-2 (2015)*
Tabassum, S. 외, New J. Chem., 2017, 41, 3515-3523*
Thakran, A. K. 와, Int. J. Pharm. Sci. Res. 2012, 3,: 213-217*
Tremblay-Morin, J.-P. 외, Tetrahedron Lett. 2004, 45, 3471-3474*
Yadav, J. D. 외, J. Mol. Cat. A: Chem. 2007, 274, 101-104*

Also Published As

Publication number Publication date
WO2018194520A9 (en) 2019-10-17
IL270078B (en) 2022-09-01
US20200131139A1 (en) 2020-04-30
WO2018194520A1 (en) 2018-10-25
JP2020517745A (ja) 2020-06-18
EP3612518A1 (en) 2020-02-26
GB201706162D0 (en) 2017-05-31
JP7423010B2 (ja) 2024-01-29
CA3060939A1 (en) 2018-10-25
US11292773B2 (en) 2022-04-05
CN110719906A (zh) 2020-01-21
MX2024000001A (es) 2024-02-20
KR20200029384A (ko) 2020-03-18
AU2018256285B2 (en) 2022-08-04
RU2019135562A (ru) 2021-05-19
SG11201909418WA (en) 2019-11-28
AU2018256285A1 (en) 2019-11-07
CN110719906B (zh) 2023-07-28
IL270078A (https=) 2019-12-31
RU2019135562A3 (https=) 2021-07-21
BR112019022015A2 (pt) 2020-05-12
EP3612518A4 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
WO2018137639A1 (zh) 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
JP6787899B2 (ja) 医薬的活性化合物
MX2015002887A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013235425A1 (en) Inhibition of MCL-1 and/or BFL-1/A1
KR102753110B1 (ko) Bcl-2-관련된 데스 프로모터(bad) 인산화의 소분자 억제제
Li et al. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition
PT1636215E (pt) Furazanobenzimidazoles
WO2019056120A1 (en) PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF
KR20240158305A (ko) Pcna 억제제 및 이의 용도
Srinivas et al. Design and synthesis of quinoxaline-piperazine-pyrazolo conjugates as VEGFR-2 targeting agents and ADMET studies
RU2799873C9 (ru) Низкомолекулярные ингибиторы фосфорилирования BCL-2-ассоциированного промотора смерти (BAD)
RU2799873C2 (ru) Низкомолекулярные ингибиторы фосфорилированные BCL-2-ассоциированного промотора смерти (BAD)
JP6034880B2 (ja) オーロラおよびｆｌｔ３キナーゼモジュレーター
EP3568391B1 (en) Benzene disulfonamide for the treatment of cancer
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
BR112019022015B1 (pt) Inibidores de moléculas pequenas de fosforilação de promotor de morte associado a bcl-2 (bad)
WO2022249120A1 (ko) 신규한 벤조인돌론 화합물 및 이를 포함하는 약학적 조성물
JP6853833B2 (ja) エストロゲン受容体調節物質の組合せ
Lu et al. Rational design and development of novel NAE inhibitors for the treatment of pancreatic cancer
AU2014327311B2 (en) Compounds useful in the treatment of neoplastic diseases
JP2020529451A (ja) 増殖性疾患の処置のためのｓｔａｔ３阻害剤としてのスルホンアミド誘導体
Al-Masoudi et al. Synthesis, anticancer, antioxidant activities and in silico studies of novel benzhydrylpiperazine bearing Δ 2-1, 2, 3-triazoline hydrides
Hu et al. Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent
JP2025508014A (ja) 新規ヘテロ環化合物およびそれを含む薬学的組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231004

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240405

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241230

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250107

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration